Texas Senate Bill SB913

Texas 2011 - 82nd Regular

• Out of Senate Committee: 4/11/11
• Introduced: 2/24/11
• Voted on by Senate: 4/21/11
• Refer: 3/8/11
• Report Pass: 4/11/11
• Engrossed: 4/21/11
• Refer: 4/26/11
• Report Pass: 5/17/11

Caption

Relating to the transmission of records regarding over-the-counter sales of ephedrine, pseudoephedrine, and norpseudoephedrine and a person's civil liability for certain acts arising from the sale of those products.

Impact

Once enacted, SB913 is expected to significantly amend the existing framework of the Health and Safety Code in Texas by tightening regulations on the sale of products containing ephedrine and its derivatives. By mandating real-time logging of sales, the bill aims to curb the over-the-counter acquisition of these substances for illicit manufacturing of methamphetamine and other drugs. The bill will also provide a mechanism for businesses to fulfill their legal responsibilities while minimizing risks associated with civil liability during sales interactions, strengthening drug control measures and enhancing public safety.

Summary

SB913 is a legislative proposal that addresses the transmission of records regarding the over-the-counter sales of drugs containing ephedrine, pseudoephedrine, and norpseudoephedrine. The bill intends to establish a real-time electronic logging system that enables pharmacies and law enforcement agencies to communicate and monitor sales, thereby preventing illegal purchases and potential misuse of these products. The bill includes provisions for maintaining records, identifying purchasers, and ensuring compliance with state and federal regulations pertaining to these controlled substances.

Contention

Notable points of contention surrounding SB913 involve concerns about privacy, costs of implementation for pharmacies, and the potential for operational difficulties with the real-time logging system. Critics might argue that mandatory electronic logging could burden small businesses, leading to increased operational costs while also raising concerns about data security and the management of sensitive purchaser information. Furthermore, discussions may arise regarding the effectiveness of such measures in actually preventing drug abuse versus merely limiting legal access to necessary medications for consumers.